659MO Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC)

Chanzá, Nieves Martínez; Carnot, Aurélien; Barthélémy, Philippe; Casert, Vinciane; Sautois, Brieuc; Brande, Jan Van den; Vanhaudenarde, Vincent; Staudacher, L.; Seront, Emmanuel; Culine, Stéphane; Gizzi, Marco; Gil, Thierry; Paesmans, Marianne; Kotecki, Nuria; Ignatiadis, M.; Albisinni, Simone; Fantoni, Jean-Christophe; Tricard, Thibault; Roumeguère, Thierry; Awada, Ahmad

doi:10.1016/j.annonc.2021.08.055

Cited by 7 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most studies were phase II single-arm trials and carried out within the last six years. Two RCTs scored 6 points by the modified Jadad scale and were regarded to be high-quality ( 14 , 15 ). The other single-arm designed studies were assessed as acceptable for the meta-analysis, with scores ranging from 12 to 15 points by the MINORS index.…”

Section: Resultsmentioning

confidence: 99%

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer

et al. 2022

View full text Add to dashboard Cite

ObjectiveConsidering the striking evidence revealed by immunotherapy in advanced or metastatic bladder cancer, investigators have explored neoadjuvant immunotherapy and chemoimmunotherapy in muscle-invasive bladder cancer (MIBC). Currently, there have been a large number of studies reporting varied efficacy and safety of these approaches. Herein, we pooled the available evidence in terms of oncological outcomes (pathological complete response [pCR] and pathological partial response [pPR]) and safety outcomes (immune-related adverse events [irAEs], treatment-related adverse events [TRAEs]), through a systematic review and meta-analysis.MethodWe searched PubMed, Embase, Cochrane Library, and American Society of Clinical Oncology meeting abstracts to identify relevant studies up to June 2022. Studies were included if they evaluated the neoadjuvant immunotherapy or chemoimmunotherapy in MIBC and reported at least the pCR.ResultsA total of 22 records involving 843 patients were included. For pCR of immunotherapy, the pooled rate of immune checkpoint inhibitor (ICI) monotherapy and dual-ICIs therapy was 24% (95% confidence interval [CI]: 15.3% - 32.8%) and 32.1% (95%CI: 20.6% - 43.7%), respectively. For pCR of chemoimmunotherapy, the overall pooled rate was 42.6% (95% CI: 34.9% - 50.2%). Subgroup of gemcitabine/cisplatin (GC) plus ICI had a pCR rate of 41.7% (95%CI: 35.8% - 47.5%). In terms of safety, the pooled rate of Grade≥3 irAEs was 11.7% (95% CI: 6.5%-16.9%). In subgroup analysis, the Grade≥3 irAEs rate of ICI monotherapy, dual-ICIs therapy, and GC plus ICI therapy was 7.4% (95% CI: 4.3%-10.5%), 30.3% (95% CI: 15.3%-45.3%), and 14.5% (95% CI: 3.5% - 25.4%), respectively. Besides, the pooled Grade≥3 TRAEs rate for chemoimmunotherapy was 32.4% (95% CI: 13.1% - 51.6%).ConclusionNeoadjuvant immunotherapy and chemoimmunotherapy were effective and safe in the treatment of MIBC. Compared to ICI monotherapy, dual-ICIs therapy or chemoimmunotherapy can improve the response rate, while increasing the morbidity of Grade≥ 3 irAEs or Grade≥ 3 TRAEs.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD4202233771.

show abstract

Section: Resultsmentioning

confidence: 99%

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In HCRN GU14-188 study cohort one, the rate of pathologic muscle invasive response (PaIR) rate of neoadjuvant treatment of pembrolizumab combined with GC regimen was 61.1% ( 72 ). The pCR rate in the AURA study comparing dd-MAVC + avelumab (A) to GC + avelumab (A) was 54% for dd-MAVC + A and 50% for GC + A ( 73 ). A pDS rate of up to 76.5% and a pCR rate of 58.8% were reported in the abstract of the BGB-A317-2002 research, which was published in 2022.…”

Section: Chemotherapy Combined With Immunotherapymentioning

confidence: 99%

A narrative review of management of muscle-invasive bladder cancer perioperative period: will continuous and combined treatment be the new trend?

Lan,

Ran,

Gao

et al. 2024

Transl Androl Urol

View full text Add to dashboard Cite

Background and Objective With the emergence of immunotherapy and targeted therapies, there are more options for the perioperative period management of muscle-invasive bladder cancer (MIBC), and various types of clinical studies are emerging, leading to the need to explore ways to choose the optimal treatment modality. This review aims to synthesize past and present treatment modalities and to explore future trends in the perioperative period cares of MIBC for the benefit of clinical practitioners. Methods A non-systematic, literature search was conducted between March 5, 2023 and November 30, 2023 on PubMed using “perioperative period”, “MIBC”, “chemotherapy”, “radiotherapy”, “immunotherapy”, “targeted treatment” and “combination” as keywords, along with a search for ongoing clinical studies that were related to the perioperative period of MIBC on classic.clinicaltrials.gov, some latest conference abstracts were also included as references. Key Content and Findings The trend towards benefit from adjuvant chemotherapy in perioperative chemotherapy is gradually being recognized. Neoadjuvant immunotherapy, including single-agent immunization, like programmed cell death protein 1 (PD-1) inhibitors, programmed cell death 1 ligand 1 (PD-L1) inhibitors and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, and double-immunization, has been confirmed by several clinical studies to be beneficial to clinical remission rates, and the combination regimen is superior to single-agent therapy. Targeted therapies such as antibody-drug conjugate (ADC) are entering MIBC perioperative studies. Multiple sequential and combination clinical studies are gradually disclosing preliminary data on efficacy and safety. Conclusions Immunotherapy would become an essential perioperative treatment for MIBC, and continuous and integrated perioperative management may become the MIBC treatment mode of the future. ADC medicines will also be a hot research focus in the coming years.

show abstract

“…Erste Ergebnisse dieser Kohorte wurden 2022 auf dem ASCO-Meeting (American Society of Clinical Oncology) präsentiert. Im Arm A betrug die Rate an pathologischen Komplettremissionen 18 % (95 %-KI: 6-37), in Arm B dagegen 36 % (95 %-KI: 19-56; [12]).…”

Section: Kombinierte Immunchemotherapieunclassified

Stellenwert der Immuntherapie in der perioperativen Behandlung des lokalisierten muskelinvasiven Harnblasenkarzinoms

et al. 2022

View full text Add to dashboard Cite

ZusammenfassungImmun-Checkpoint-Inhibitoren (ICI) sind als Erst- und Zweitlinientherapien beim metastasierten bzw. lokal fortgeschrittenen Urothelkarzinom als Standard etabliert. Der perioperative Einsatz der Immuntherapie steht nun im Fokus aktueller Entwicklungen und Forschung in der Uroonkologie. Aktuelle Studien untersuchen ICI als Monotherapie oder in Kombination mit Chemotherapie oder Bestrahlung im perioperativen Setting. Dieser Artikel soll einen Überblick über die neuen Studienkonzepte, die aktuell publizierten Daten und daraus entstehenden Therapiekonzepte sowie einen Ausblick auf zukünftige Entwicklungen bieten.

show abstract

659MO Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC)

Abstract: 659MOAvelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC)

Cited by 7 publications

References 0 publications

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer

A narrative review of management of muscle-invasive bladder cancer perioperative period: will continuous and combined treatment be the new trend?

Stellenwert der Immuntherapie in der perioperativen Behandlung des lokalisierten muskelinvasiven Harnblasenkarzinoms

Contact Info

Product

Resources

About